Abstract 1337
Background
Standard guidelines recommend mutation testing for KRAS, NRAS and BRAF in MCRC. POG at BC Cancer is an investigational project that performs WGTA to identify potential hypothetical actionable biomarkers. We aimed to determine its clinical significance compared to standard sequencing panels by analyzing the prevalence of actionable variants and their impact on treatment decisions.
Methods
We analyzed 69 POG MCRC patients (pts) and summarized their WGTA results to identify germline and somatic coding variants, copy number alterations, structural alterations and gene expression outliers. Actionable items were defined as variants that could direct therapy with an investigational or approved agent, and were classified as either standard (found in local sequencing panel- BC Oncopanel) or expanded (not in Oncopanel).
Results
74% of pts received 2 or more prior lines of chemotherapy. 1 pt died before biopsy was made available and 1 pt had an unsuccessful biopsy. Remaining analysis of 67 pts revealed 49 (73%) pts with actionable alterations, of which 43% consisted of mutation changes, 40% expression changes, 14% copy number variants, and 3% high mutational burden or HRD. Most common standard alterations (54%) were mutations in TP53, KRAS, BRAF, PIK3CA and most common expanded items (46%) were high expression of FGFR1/3, FLT1/3, and VEGFA/B. Among these, 13 (27%) pts had alterations that led to standard chemotherapy or anti-EGFR based treatment, and 7 (14%) pts had a variant that resulted in non-standard therapies. Of those, only irbesartan, targeting the FOS-JUN pathway, resulted in a meaningful response duration of 28 months, while the remaining had an average PFS of 1.7 month. 29 (59%) pts did not receive therapy outlined in POG analysis due to lack of access for the target drug (n = 15), poor performance status (n = 7), and patient or physician preference (n = 7).
Conclusions
WGTA in MCRC provided additional understanding of tumor biology, with high rates of expression changes not otherwise captured in standard sequencing panel. However, at the present time, there is limited additional clinical therapeutic benefit in comparison. Future development is needed and ongoing.
Clinical trial identification
Legal entity responsible for the study
BC Cancer.
Funding
BC Cancer Foundation.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1310 - Lymphocytes express receptor tyrosine kinases in patients with renal cell carcinoma and healthy donors
Presenter: Ilya Tsimafeyeu
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1596 - Oncogenes analysis using GO-based clustering
Presenter: Dmitriy Babenko
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5181 - PNU-74654 enhances the antiproliferative effects of 5-FU in breast cancer and antagonizes thrombin induced cell growth via the Wnt Pathway
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3344 - P21 has the potential to become the monitoring marker for the CDK4/6 inhibitors resistance in breast cancer
Presenter: Masafumi Iida
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
894 - Overexpression of NAMPT in adult T-cell leukemia/lymphoma patients and anti-tumor activity of a NAMPT inhibitor in vivo
Presenter: Tomohiro Kozako
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2224 - 9-ING-41, a clinically relevant inhibitor of Glycogen Synthase Kinase-3 (GSK-3), is active pre-clinically in human bladder and renal cell cancers
Presenter: Hiroo Kuroki
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3380 - A new natural compound identified with metabolomic approach has cytotoxic activity against human colorectal cancer cell lines with acquired resistance to cetuximab
Presenter: Vincenzo De Falco
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4713 - Multiple Myeloma Metal Levels and Proteasome Activity
Presenter: Kai Uwe Stumpf
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4134 - A translational drug-screening tool for interrogating the effect of anti-TGF-_ therapy on fibroblast activity and the desmoplastic reaction
Presenter: Neel Nissen
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2736 - Eribulin demonstrate selectively high sensitivity to recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) cells and xenograft tumors
Presenter: hiroko kitahara
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract